114 related articles for article (PubMed ID: 35088663)
1. Effects of Astragaloside IV on the Pharmacokinetics of Metoprolol in Rats and its Mechanism.
Shi Z; Jiang J; Zhao D; Xie B; Li Y; Yu C
Curr Drug Metab; 2022; 23(2):131-136. PubMed ID: 35088663
[TBL] [Abstract][Full Text] [Related]
2. Inhibitory effects of fluoxetine and duloxetine on the pharmacokinetics of metoprolol in vivo and in vitro.
Xu T; Gao N; Li Y; Wang R; Chen B; Hu G; Zhang X
Fundam Clin Pharmacol; 2022 Dec; 36(6):1057-1065. PubMed ID: 35510497
[TBL] [Abstract][Full Text] [Related]
3. In Vitro CYP2D Inhibitory Effect and Influence on Pharmacokinetics and Pharmacodynamic Parameters of Metoprolol Succinate by Terminalia arjuna in Rats.
Varghese A; Savai J; Mistry S; Khandare P; Barve K; Pandita N; Gaud R
Drug Metab Lett; 2016; 10(2):124-35. PubMed ID: 26891872
[TBL] [Abstract][Full Text] [Related]
4. Enhanced oral bioavailability of metoprolol with gallic acid and ellagic acid in male Wistar rats: involvement of CYP2D6 inhibition.
Athukuri BL; Neerati P
Drug Metab Pers Ther; 2016 Dec; 31(4):229-234. PubMed ID: 27875319
[TBL] [Abstract][Full Text] [Related]
5. Lotus leaf alkaloid fraction can strongly inhibit CYP2D6 isoenzyme activity.
Ye LH; Kong LT; Yan MZ; Cao FR; Wang LS; Liao YH; Pan RL; Chang Q
J Ethnopharmacol; 2016 Dec; 194():913-917. PubMed ID: 27771456
[TBL] [Abstract][Full Text] [Related]
6. Influence of CYP2D6*10 on the pharmacokinetics of metoprolol in healthy Korean volunteers.
Jin SK; Chung HJ; Chung MW; Kim JI; Kang JH; Woo SW; Bang S; Lee SH; Lee HJ; Roh J
J Clin Pharm Ther; 2008 Oct; 33(5):567-73. PubMed ID: 18834373
[TBL] [Abstract][Full Text] [Related]
7. Effects of astragaloside IV on the pharmacokinetics of puerarin in rats.
Liu L; Li P; Qiao L; Li X
Xenobiotica; 2019 Oct; 49(10):1173-1177. PubMed ID: 29790819
[No Abstract] [Full Text] [Related]
8. Mechanism-Based Inactivation of CYP2D6 by Phellopterin and Related Drug-Drug Interaction with Metoprolol.
Cheng Z; He Y; Chen Y; Zhao G; Liu Y; Zhang J; Li X; Ran G; Zhang Q; Peng Y; Li W; Zheng J
J Agric Food Chem; 2024 Jan; 72(3):1745-1755. PubMed ID: 38214270
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic and pharmacodynamic interactions between metoprolol and dronedarone in extensive and poor CYP2D6 metabolizers healthy subjects.
Damy T; Pousset F; Caplain H; Hulot JS; Lechat P
Fundam Clin Pharmacol; 2004 Feb; 18(1):113-23. PubMed ID: 14748763
[TBL] [Abstract][Full Text] [Related]
10. Metoprolol-pridopidine drug-drug interaction and food effect assessments of pridopidine, a new drug for treatment of Huntington's disease.
Rabinovich-Guilatt L; Steiner L; Hallak H; Pastino G; Muglia P; Spiegelstein O
Br J Clin Pharmacol; 2017 Oct; 83(10):2214-2224. PubMed ID: 28449367
[TBL] [Abstract][Full Text] [Related]
11. Effects of astragaloside IV on the pharmacokinetics of omeprazole in rats.
Liu W; Liu G; Liu J
Pharm Biol; 2019 Dec; 57(1):449-452. PubMed ID: 31290355
[No Abstract] [Full Text] [Related]
12. The effect of mirabegron, a potent and selective β3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol.
Krauwinkel W; Dickinson J; Schaddelee M; Meijer J; Tretter R; van de Wetering J; Strabach G; van Gelderen M
Eur J Drug Metab Pharmacokinet; 2014 Mar; 39(1):43-52. PubMed ID: 23728524
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of impact of Herba Erigerontis injection, a Chinese herbal prescription, on rat hepatic cytochrome P450 enzymes by cocktail probe drugs.
Han YL; Li D; Ren B; Jing GP; Meng XL; Zhou ZY; Yu Q; Li Y; Wan LL; Guo C
J Ethnopharmacol; 2012 Jan; 139(1):104-9. PubMed ID: 22079696
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic study on the co-administration of abemaciclib and astragaloside IV in rats.
Sun S; Liu L; Song H; Li H
Pharm Biol; 2022 Dec; 60(1):1944-1948. PubMed ID: 36226863
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol.
Swaisland HC; Ranson M; Smith RP; Leadbetter J; Laight A; McKillop D; Wild MJ
Clin Pharmacokinet; 2005; 44(10):1067-81. PubMed ID: 16176119
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of CYP2D6 by quinidine and its effects on the metabolism of cilostazol.
Bramer SL; Suri A
Clin Pharmacokinet; 1999; 37 Suppl 2():41-51. PubMed ID: 10702886
[TBL] [Abstract][Full Text] [Related]
17. Evaluation and Comparison of the Inhibition Effect of Astragaloside IV and Aglycone Cycloastragenol on Various UDP-Glucuronosyltransferase (UGT) Isoforms.
Ran R; Zhang C; Li R; Chen B; Zhang W; Zhao Z; Fu Z; Du Z; Du X; Yang X; Fang Z
Molecules; 2016 Nov; 21(12):. PubMed ID: 27916843
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.
Zineh I; Beitelshees AL; Gaedigk A; Walker JR; Pauly DF; Eberst K; Leeder JS; Phillips MS; Gelfand CA; Johnson JA
Clin Pharmacol Ther; 2004 Dec; 76(6):536-44. PubMed ID: 15592325
[TBL] [Abstract][Full Text] [Related]
19. Astragaloside IV inhibited the activity of CYP1A2 in liver microsomes and influenced theophylline pharmacokinetics in rats.
Zhang YH; Zhang YJ; Guo YL; Li WJ; Yu C
J Pharm Pharmacol; 2013 Jan; 65(1):149-55. PubMed ID: 23215698
[TBL] [Abstract][Full Text] [Related]
20. A meta-analysis of CYP2D6 metabolizer phenotype and metoprolol pharmacokinetics.
Blake CM; Kharasch ED; Schwab M; Nagele P
Clin Pharmacol Ther; 2013 Sep; 94(3):394-9. PubMed ID: 23665868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
